Life Science Webinars

  1. Biologics Manufacturing - Is Your Company Ready?
    3/9/2017

    This webcast will not only reveal the current trends and challenges in Biologics manufacturing, but also new business models and how technology can drive high quality and operational efficiency. 

  2. Process of the Future: Cheaper, Faster and Safer With Single-Use
    2/27/2017

    Cell culture transfer from one vial to containers such as T-flasks or shake flasks, and then to the bioreactor, is usually one of these open phases. These critical steps may take several days or even weeks, and can results in delays if a contamination occurs.

  3. An Alternative To Achieve Speed And Scalability To Microbial Expression For Next-Gen Therapeutics
    2/17/2017

    The newly developed G1-3 fermentation process makes use of short, straightforward fermentation regimes for optimized space time yield.

  4. Biosimilars: Regulatory Trends and Quality Control Testing Requirements
    1/30/2017

    This webinar will review regulatory expectations in assessing the comparability of biosimilars through protein chemistry techniques and cell based bioassays. Key considerations for developing robust bioassays for biosimilar comparison will be presented.

  5. How To Make Novel Therapies A Reality In Tomorrow's Complex Biopharma Landscape
    12/23/2016

    A recent survey conducted by the Economist Intelligence Unit highlights the new products that the biopharma industry identifies as most disruptive to their growth strategies in the next five years. The findings raise a challenge to biopharma to go beyond barriers to bringing new products to market by presenting ways to overcome these hurdles and make novel therapies a reality.

  6. The Practical Application Of Home Healthcare
    10/4/2016

    Recruiting patients and retaining their participation in a clinical trial remain the biggest challenges faced by pharmaceutical companies when developing new medicines. For a patient, participation in a clinical trial can be stressful and burdensome, resulting in one in four patients dropping out of a clinical trial prior to completion. With sponsors facing tight-timelines, increased regulatory scrutiny and spiralling budgets the desire to address these challenges has never been more prominent.

  7. Modeling Time-Dependent Processes More Accurately To Improve Quality And Control
    9/28/2016

    Batch processes are common in pharmaceutical, biopharmaceutical, food, beverage and chemical industries. When building models across various batches one may often encounter varying batch lengths and the batches may start from various relative points of time in a chemical context. Batch Modeling is important for process development and understanding the process for batch similarity and why some batches give a product quality outside the specifications.

  8. Integrating Safety And Immunogenicity Assessments Into The Biopharma Preclinical Development Process
    9/27/2016

    Efficacy, safety, immunogenicity and manufacturability issues play a large role in the high attrition rate of biopharmaceutical candidates each year. To help reduce the risk of failure, tools to address the developability of preclinical candidates have been established.

  9. The Implications Of Inaccurate Forecasting In Biologic Drug Substance Manufacturing And Strategies To Mitigate Risks
    9/2/2016

    The biopharmaceutical market is undergoing tremendous transformation. Speed to develop and manufacture product has become a critical driver with increased competition and the pressure to be first to market. New process technologies, advances in cell line development and more targeted and complex therapeutic classes have created a challenging biopharmaceutical manufacturing environment with new capacity requirements.

  10. Facilitate Risk Assessment For Excipients With EMPROVE®
    8/9/2016

    The webinar will explore: the EU risk assessment guideline for excipients, suppliers' and pharmaceutical companies' roles and responsibilities in the risk assessment process, and the Emprove® Program: New regulatory documentation that supports a risk-based approach.